Stocks · News reference
Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of $(0.41) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 12:01 PM
- Checked
- Aug 6, 2026, 12:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
Read original at benzingaBMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
Read original at benzingaHC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Read original at benzinga